All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GB0139
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 07, 2020
Details:
Galecto's initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 to treat fibrosis. Its lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 for the treatment of severe fibrotic lung diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GB0139
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Soleus Capital
Deal Size: $64.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 25, 2020
Details:
Galecto intends to use the funds to prepare for a potential conditional approval of GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in the European Union and to further expand and advance its clinical development pipeline.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GB0139
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
Galecto has received Orphan Drug Designation (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for GB0139 in the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GB0139
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
Details:
The results showed that GB0139 is highly effective in the bleomycin model, including pharmacodynamic evidence with reduction of galectin-3.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
